Viewing nowCombinationJanugluem XR Extended-Release Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.

MFDS item code 202300594 · Approved 2023.02.17 · Insurance code 651205970
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. Sitagliptin and metformin work together to effectively improve blood glucose levels. Therefore, it is beneficial for patients requiring blood glucose management and is used in the overall treatment of diabetes.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases of incomplete dissolution of this drug followed by excretion in the feces have been reported. It is not known whether the material excreted in the feces contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Should Not Take This Drug). 2. Patients receiving metformin treatment: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start with their current doses of sitagliptin and metformin. - Patients who have been receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in a type 2 diabetes treatment regimen may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Should Not Take This Drug).
This drug is a combination product containing sitagliptin and metformin, used for the treatment of type 2 diabetes. Firstly, sitagliptin can rarely cause severe allergic reactions, such as anaphylaxis, angioedema, and serious skin diseases, so if such symptoms occur, the medication should be stopped immediately. Also, there may be a risk of acute pancreatitis, so if symptoms such as abdominal pain or vomiting occur after taking the medication, consult a healthcare professional immediately. Metformin can cause lactic acidosis, a rare but serious metabolic complication, particularly at risk in patients with impaired kidney function or liver dysfunction. Thus, patients with moderate or worse kidney impairment, severe infections or dehydration, and heart failure should not use this drug. This drug is not recommended for use in pregnant or breastfeeding women, or in children under 18 years of age. During treatment, regular meals and exercise are important, and attention should be paid to symptoms of hypoglycemia. In particular, when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, so blood glucose should be monitored frequently, and drug dosage adjustments may be necessary. Additionally, alcohol consumption should be avoided while taking this drug, and prior to undergoing surgery or imaging tests with contrast agents, healthcare professionals should be informed to temporarily discontinue the medication. Patients should have regular kidney function tests and consult healthcare professionals immediately if any unusual symptoms occur. Finally, this drug may rarely cause side effects such as joint pain, skin rash, or muscle pain, and if these symptoms persist or worsen, patients should inform their healthcare provider.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container and in a place that avoids moisture. A storage temperature between 1 degree and 30 degrees Celsius at room temperature is appropriate. Storing it this way helps maintain the drug's effectiveness.
Bright green oval extended-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samchundang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.